CompletedPhase 1

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Switzerland18 participantsStarted 2010-07

Plain-language summary

RATIONALE: Nelfinavir mesylate and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of hematologic cancer by blocking blood flow to the cancer. Giving nelfinavir mesylate together with bortezomib may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of nelfinavir mesylate when given together with bortezomib in treating patients with relapsed or progressive advanced hematologic cancer.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosed with advanced hematologic malignancies meeting the following criteria: * Multiple myeloma * Received ≥ 2 lines of prior chemotherapy (induction chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant with or without maintenance therapy is considered one line of therapy) * Acute myeloid leukemia * Acute lymphoblastic leukemia * Diffuse large B-cell lymphoma * Hodgkin lymphoma * Mantle cell lymphoma * Mature T- and NK-cell neoplasms restricted to the following WHO-defined entities: * T-cell prolymphocytic leukemia * T-cell large granular lymphocytic leukemia * Aggressive NK-cell leukemia * Adult T-cell leukemia/lymphoma * Extranodal NK/T-cell lymphoma (nasal type) * Mycosis fungoides * Sézary syndrome * Primary CD30-positive T-cell lymphoproliferative disorders * Primary cutaneous anaplastic large cell lymphoma * Primary cutaneous gamma-delta T-cell lymphoma * Peripheral T-cell lymphoma (not otherwise specified) * Angioimmunoblastic T-cell lymphoma * Anaplastic large cell lymphoma (ALK-positive/ALK-negative) * Grade 3B follicular lymphoma * Relapsed following or progressed during standard therapy * Meeting the following criteria: * Standard intensive therapy is not feasible * Current disease state for which there is no standard effective therapy * Refused standard therapy where no curative option exists * Measurable disease, defined…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Dose limiting toxicity

Timeframe: during first cycle

Trial details

NCT IDNCT01164709

SponsorSwiss Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-07

View on ClinicalTrials.gov More Leukemia trials